Schaffung von Exzellenzzentren in Patient Blood Management - APA

(186) Feagan BG, Wong CJ, Kirkley A, Johnston DW, Smith FC, Whitsitt P, et al. Erythropoietin with
iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A
randomized, controlled trial. Ann Intern Med 2000 Dec 5;133(11):845-54.
(187) Zarychanski R, Houston DSMP. Anemia of chronic disease: A harmful disorder or an adaptive,
beneficial response? CMAJ 2008 Aug 12;179(4):333-7.
(188) Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of
Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart
Failure. Circulation 2003 Jan 21;107(2):294-9.
(189) Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and
harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
CMAJ 2009 May 26;180(11):E62-E71.
(190) Jin B, Luo X, Lin H, Li J, Shi H. A meta-analysis of erythropoiesis-stimulating agents in
anaemic patients with chronic heart failure. European Journal of Heart Failure 2010
Mar;12(3):249-53.
(191) Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of
epoetin alfa in critically ill patients. N Engl J Med 2007 Sep 6;357(10):965-76.
(192) Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin-receptor agonists in
critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007 Sep
25;177(7):725-34.
(193) Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin
levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003
May;63(5):1908-14.
(194) Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and
patient outcomes. Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S133-S141.
(195) Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects
of normal as compared with low hematocrit values in patients with cardiac disease who are
receiving hemodialysis and epoetin. N Engl J Med 1998 Aug 27;339(9):584-90.
(196) Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de ZD, Eckardt KU, et al. A trial of
darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009
Nov;%19;361(21):2019-32.
(197) Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat
head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind,
placebo-controlled trial. Lancet 2003 Oct 18;362(9392):1255-60.
(198) Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al.
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with
metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005
Sep 1;23(25):5960-72.
(199) Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, doubleblind,
placebo-controlled trial of erythropoietin in non-small-cell lung cancer with diseaserelated
anemia. J Clin Oncol 2007 Mar;%20;25(9):1027-32.
(200) Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-Stimulating Agents -- Time for
a Reevaluation. N Engl J Med 2010 Jan 21;362(3):189-92.
(201) Aronson D, Suleiman M, Agmon Y, Suleiman A, Blich M, Kapeliovich M, et al. Changes in
haemoglobin levels during hospital course and long-term outcome after acute myocardial
infarction. Eur Heart J 2007 Jun;28(11):1289-96.
(202) Andrews T, Waterman H, Hillier V. Blood gas analysis: a study of blood loss in intensive care.
J Adv Nurs 1999;30:851-7.
76